US Patent Issued to GUANGZHOU BIO-GENE TECHNOLOGY on Dec. 30 for "Chimeric antigen receptor targeting CLL1 and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,508,312, issued on Dec. 30, was assigned to GUANGZHOU BIO-GENE TECHNOLOGY Co. LTD (Guangdong, China).

"Chimeric antigen receptor targeting CLL1 and use thereof" was invented by Guangchao Li (Guangdong, China), Min Luo (Guangdong, China), Wen Ding (Guangdong, China), Zhao Zhou (Guangdong, China) and Xuejun Wang (Guangdong, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a chimeric antigen receptor targeting CLL1 and an application thereof. The chimeric antigen receptor targeting CLL1 comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain; the antigen binding domain is an anti-CLL1 ant...